Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

19.96 -0.48 (-2.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
Technical Analysis : Pinduoduo (PINS) & Intellia Therapeutics (NTLA)
Here's a technical analysis of two stocks: Pinduoduo (PDD) & Intellia Therapeutics. 
Via Talk Markets
CareDx & Intellia Therapeutics Elliott Wave Analysis
At this point the flat correction into wave (4) could be completed, if not we are just missing one last leg down. 
Via Talk Markets
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
US Stocks: AME, AVAV, NIO, NTLA, PDD & SNAP Technical Analysis
Technical stocks analysis: Ametek, AeroVironment, Nio Inc, Intellia Therapeutics, Pinduoduo, and Snap. 
Via Talk Markets
Where Intellia Therapeutics Stands With Analysts
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst rati... 
Via Benzinga
Why Intellia Therapeutics' Stock Is Trading Higher Today
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading si... 
Via Benzinga
Why Intellia Therapeutics Shares Are Trading Higher Today
... 
Via Benzinga
Unusual Options Activity Insight: Intellia Therapeutics
On Friday, shares of Intellia Therapeutics (NASDAQ:NTLA) ... 
Via Benzinga
Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript
NTLA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
10 Biggest Price Target Changes For Friday
Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading. Needham cut the price... 
Via Benzinga
Why Shares of Intellia Therapeutics Are Jumping Today
More progress in the pipeline has investors bullish on the company's shares. 
Via The Motley Fool
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap. 
Via The Motley Fool
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding
It's a good time to be a gene-editing company. 
Via The Motley Fool
Russell 2000 Traders Place Bearish Bets Via IWM ETF
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM... 
Via Benzinga
WHO Issues Framework For Governance For Gene Editing Technologies
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
There are still some key unanswered questions for the biotech's promising gene-editing therapy. 
Via The Motley Fool
US Stocks Technical Analysis: AVAV, ESLT, ICE, HDFC, NTLA & NVDA
Elliott Wave Technical Analysis for AeroVironment, Elbit Systems, Intercontinental Exchange, HDFC Bank Limited, Intellia Therapeutics, and Nvidia. 
Via Talk Markets
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
Here's Why Regeneron Gained 11% Last Month
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands. 
Via The Motley Fool
2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed. 
Via The Motley Fool
Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus
The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped. 
Via Investor's Business Daily
Topics Initial Public Offering Stocks
Here's What Drove Gene Editing Stocks Higher This Week
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers. 
Via The Motley Fool
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.